{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:21:45Z","timestamp":1791404505933,"version":"4.3.3"},"reference-count":246,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"am","delay-in-days":305,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/MED-QUI\/29164\/2017"],"award-info":[{"award-number":["PTDC\/MED-QUI\/29164\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/145637\/2019"],"award-info":[{"award-number":["SFRH\/BD\/145637\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/00081\/2020"],"award-info":[{"award-number":["UIDB\/00081\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04378\/2020"],"award-info":[{"award-number":["UIDB\/04378\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011929","name":"Programa Operacional Tem\u00e1tico Factores de Competitividade","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011929","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.arr.2022.101658","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T12:52:04Z","timestamp":1654174324000},"page":"101658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":92,"special_numbering":"C","title":["Brain drug delivery and neurodegenerative diseases: Polymeric PLGA-based nanoparticles as a forefront platform"],"prefix":"10.1016","volume":"79","author":[{"given":"Miguel","family":"Pinto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Barreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Remi\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arr.2022.101658_bib1","series-title":"Engineering of Biomaterials for Drug Delivery Systems","first-page":"363","article-title":"PEGylation and its alternatives: a summary","author":"Abbina","year":"2018"},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood\u2013brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2022.101658_bib3","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.nano.2018.09.010","article-title":"Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer's disease brain","volume":"16","author":"Ahlschwede","year":"2019","journal-title":"Nanomedicine"},{"issue":"13","key":"10.1016\/j.arr.2022.101658_bib4","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/10826076.2017.1343735","article-title":"Rasagiline-encapsulated chitosan-coated PLGA nanoparticles targeted to the brain in the treatment of parkinson's disease","volume":"40","author":"Ahmad","year":"2017","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"issue":"4","key":"10.1016\/j.arr.2022.101658_bib5","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1021\/mp800051m","article-title":"Factors affecting the clearance and biodistribution of polymeric nanoparticles","volume":"5","author":"Alexis","year":"2008","journal-title":"Mol. Pharm."},{"issue":"5665","key":"10.1016\/j.arr.2022.101658_bib6","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1126\/science.1095833","article-title":"Drug delivery systems: entering the mainstream","volume":"303","author":"Allen","year":"2004","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.arr.2022.101658_bib7","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a002584","article-title":"Physiology and function of the tight junction","volume":"1","author":"Anderson","year":"2009","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.arr.2022.101658_bib8","doi-asserted-by":"crossref","unstructured":"Anon, 2020. Alzheimer's disease facts and figures. Alzheimers Dement. (2020), \u3008https:\/\/doi.org\/10.1002\/alz.12068\u3009.","DOI":"10.1002\/alz.12068"},{"issue":"3","key":"10.1016\/j.arr.2022.101658_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10143","article-title":"Nanoparticles in the clinic: an update","volume":"4","author":"Anselmo","year":"2019","journal-title":"Bioeng. Transl. Med."},{"issue":"6","key":"10.1016\/j.arr.2022.101658_bib10","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/10837450.2020.1740257","article-title":"In vitro and in vivo evaluation of levodopa-loaded nanoparticles for nose to brain delivery","volume":"25","author":"Arisoy","year":"2020","journal-title":"Pharm. Dev. Technol."},{"issue":"4","key":"10.1016\/j.arr.2022.101658_bib11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2174\/1567201043334605","article-title":"Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery","volume":"1","author":"Avgoustakis","year":"2004","journal-title":"Curr. Drug Deliv."},{"issue":"4","key":"10.1016\/j.arr.2022.101658_bib12","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.neuron.2018.01.021","article-title":"Multiple sclerosis: mechanisms and immunotherapy","volume":"97","author":"Baecher-Allan","year":"2018","journal-title":"Neuron"},{"issue":"11","key":"10.1016\/j.arr.2022.101658_bib13","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/dneu.20954","article-title":"Extracellular matrix and matrix receptors in blood-brain barrier formation and stroke","volume":"71","author":"Baeten","year":"2011","journal-title":"Dev. Neurobiol."},{"issue":"5","key":"10.1016\/j.arr.2022.101658_bib14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v21.i5.20","article-title":"PLGA nanoparticles in drug delivery: the state of the art","volume":"21","author":"Bala","year":"2004","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"issue":"6","key":"10.1016\/j.arr.2022.101658_bib15","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1517\/17425240902939143","article-title":"The potential for nanoparticle-based drug delivery to the brain: overcoming the blood\u2013brain barrier","volume":"6","author":"Barbu","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib16","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1080\/10717544.2017.1359862","article-title":"Nanotechnology-based drug delivery of ropinirole for Parkinson's disease","volume":"24","author":"Barcia","year":"2017","journal-title":"Drug Deliv."},{"issue":"26","key":"10.1016\/j.arr.2022.101658_bib17","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.2174\/138161211797440122","article-title":"Blood-brain barrier P-glycoprotein function in neurodegenerative disease","volume":"17","author":"Bartels","year":"2011","journal-title":"Curr. Pharm. Des."},{"issue":"12","key":"10.1016\/j.arr.2022.101658_bib18","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2174\/1381612043384844","article-title":"ABC transporters and the blood-brain barrier","volume":"10","author":"Begley","year":"2004","journal-title":"Curr. Pharm. Des."},{"issue":"6","key":"10.1016\/j.arr.2022.101658_bib19","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1172\/JCI24761","article-title":"The genetic epidemiology of neurodegenerative disease","volume":"115","author":"Bertram","year":"2005","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.arr.2022.101658_bib20","doi-asserted-by":"crossref","DOI":"10.1186\/1743-8977-7-3","article-title":"Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging","volume":"7","author":"Bhaskar","year":"2010","journal-title":"Part. Fibre Toxicol."},{"key":"10.1016\/j.arr.2022.101658_bib21","doi-asserted-by":"crossref","first-page":"6547","DOI":"10.2147\/IJN.S120939","article-title":"Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson's disease treatment","volume":"11","author":"Bi","year":"2016","journal-title":"Int. J. Nanomed."},{"issue":"41","key":"10.1016\/j.arr.2022.101658_bib22","doi-asserted-by":"crossref","first-page":"27465","DOI":"10.1021\/acsami.6b05572","article-title":"T7 peptide-functionalized PEG-PLGA micelles loaded with carmustine for targeting therapy of glioma","volume":"8","author":"Bi","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.arr.2022.101658_bib23","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/S1353-8020(09)70835-1","article-title":"Role of dopamine receptor agonists in the treatment of early Parkinson's disease","volume":"15","author":"Bonuccelli","year":"2009","journal-title":"Park. Relat. Disord."},{"issue":"3","key":"10.1016\/j.arr.2022.101658_bib24","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/15548627.2015.1136769","article-title":"Nanoparticles restore lysosomal acidification defects: Implications for Parkinson and other lysosomal-related diseases","volume":"12","author":"Bourdenx","year":"2016","journal-title":"Autophagy"},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2007.06.014","article-title":"Disulfide bridge based PEGylation of proteins","volume":"60","author":"Brocchini","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.arr.2022.101658_bib26","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jconrel.2019.03.010","article-title":"Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)\/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe\/PS1dE9 Alzheimer's disease mice model","volume":"301","author":"Cano","year":"2019","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/nnm-2020-0239","article-title":"Epigallocatechin-3-gallate PEGylated poly(lactic-co-glycolic) acid nanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice","volume":"16","author":"Cano","year":"2021","journal-title":"Nanomedicine"},{"issue":"9","key":"10.1016\/j.arr.2022.101658_bib28","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3109\/10611861003639796","article-title":"Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders","volume":"18","author":"Carroll","year":"2010","journal-title":"J. Drug Target."},{"issue":"2","key":"10.1016\/j.arr.2022.101658_bib29","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1471-4159.2009.06319.x","article-title":"The blood-brain barrier in neurodegenerative disease: a rhetorical perspective","volume":"111","author":"Carvey","year":"2009","journal-title":"J. Neurochem."},{"issue":"8","key":"10.1016\/j.arr.2022.101658_bib30","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.trac.2008.06.004","article-title":"Distribution and potential toxicity of engineered inorganic nanoparticles and carbon nanostructures in biological systems","volume":"27","author":"Casals","year":"2008","journal-title":"Trends Anal. Chem."},{"key":"10.1016\/j.arr.2022.101658_bib31","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.addr.2020.09.001","article-title":"Advances on erythrocyte-mimicking nanovehicles to overcome barriers in biological microenvironments","volume":"170","author":"Castro","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"13","key":"10.1016\/j.arr.2022.101658_bib32","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2217\/nnm-2018-0139","article-title":"Nanoparticle crossing of blood-brain barrier: a road to new therapeutic approaches to central nervous system diseases","volume":"13","author":"Cena","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.arr.2022.101658_bib33","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/978-1-60761-609-2_11","article-title":"Polymeric nanoparticles for drug delivery","volume":"624","author":"Chan","year":"2010","journal-title":"Methods Mol. Biol."},{"issue":"11","key":"10.1016\/j.arr.2022.101658_bib34","doi-asserted-by":"crossref","first-page":"9516","DOI":"10.1021\/acsami.7b01171","article-title":"Small-sized mPEG-PLGA nanoparticles of Schisantherin A with sustained release for enhanced brain uptake and Anti-Parkinsonian activity","volume":"9","author":"Chen","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"48","key":"10.1016\/j.arr.2022.101658_bib35","doi-asserted-by":"crossref","first-page":"45276","DOI":"10.1021\/acsami.9b16047","article-title":"Nanoparticles mediating the sustained puerarin release facilitate improved brain delivery to treat Parkinson's disease","volume":"11","author":"Chen","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"7","key":"10.1016\/j.arr.2022.101658_bib36","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.addr.2011.11.010","article-title":"Modern methods for delivery of drugs across the blood\u2013brain barrier","volume":"64","author":"Chen","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"6","key":"10.1016\/j.arr.2022.101658_bib37","first-page":"576","article-title":"Effect of polyoxyl 35 castor oil and Polysorbate 80 on the intestinal absorption of digoxin in vitro","volume":"50","author":"Cornaire","year":"2000","journal-title":"Arzneimittelforschung"},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib38","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2004.03.001","article-title":"Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo","volume":"278","author":"Cornaire","year":"2004","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.arr.2022.101658_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/ph14080711","article-title":"In vitro studies on nasal formulations of nanostructured lipid carriers (NLC) and solid lipid nanoparticles (SLN)","volume":"14","author":"Costa","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib40","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jconrel.2005.07.013","article-title":"Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier","volume":"108","author":"Costantino","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.arr.2022.101658_bib41","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.msec.2017.06.004","article-title":"Polymeric nanoparticles: a study on the preparation variables and characterization methods","volume":"80","author":"Crucho","year":"2017","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"issue":"89","key":"10.1016\/j.arr.2022.101658_bib42","doi-asserted-by":"crossref","first-page":"48639","DOI":"10.1039\/C4RA06406B","article-title":"Polymeric nanocarriers for expected nanomedicine: current challenges and future prospects","volume":"4","author":"Daglar","year":"2014","journal-title":"RSC Adv."},{"issue":"2","key":"10.1016\/j.arr.2022.101658_bib43","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.arr.2022.101658_bib44","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.bmc.2013.11.025","article-title":"Retinoic acid signaling pathways in development and diseases","volume":"22","author":"Das","year":"2014","journal-title":"Bioorg. Med. Chem."},{"issue":"10","key":"10.1016\/j.arr.2022.101658_bib45","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41593-018-0236-8","article-title":"Animal models of neurodegenerative diseases","volume":"21","author":"Dawson","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.arr.2022.101658_bib46","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2147\/DDDT.S138828","article-title":"Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease","volume":"12","author":"Dean","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"issue":"9","key":"10.1016\/j.arr.2022.101658_bib47","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.3390\/app11094305","article-title":"Surface functionalization of PLGA nanoparticles to increase transport across the BBB for Alzheimer\u2019s disease","volume":"11","author":"Del Amo","year":"2021","journal-title":"Appl. Sci."},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib48","doi-asserted-by":"crossref","DOI":"10.7243\/2052-6946-1-3","article-title":"Central nervous system diseases and the role of the blood-brain barrier in their treatment","volume":"1","author":"Dom\u00ednguez","year":"2013","journal-title":"Neurosci. Discov."},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1389202914666131210213042","article-title":"Molecular effects of L-dopa therapy in Parkinson\u2019s disease","volume":"15","author":"Dorszewska","year":"2014","journal-title":"Curr. Genom."},{"issue":"2","key":"10.1016\/j.arr.2022.101658_bib50","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/ana.24406","article-title":"Cerebrovascular and blood-brain barrier impairments in Huntington's disease: potential implications for its pathophysiology","volume":"78","author":"Drouin-Ouellet","year":"2015","journal-title":"Ann. Neurol."},{"issue":"2746","key":"10.1016\/j.arr.2022.101658_bib51","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/bmj.2.2746.353","article-title":"Address in pathology, on chemiotherapy: delivered before the Seventeenth International Congress of Medicine","volume":"2","author":"Ehrlich","year":"1913","journal-title":"Br. Med. J."},{"key":"10.1016\/j.arr.2022.101658_bib52","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fbioe.2020.00048","article-title":"The design of poly(lactide-co-glycolide) nanocarriers for medical applications","volume":"8","author":"Essa","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib53","doi-asserted-by":"crossref","DOI":"10.3171\/2011.10.FOCUS11252","article-title":"Focused ultrasound disruption of the blood-brain barrier: a new frontier for therapeutic delivery in molecular neurooncology","volume":"32","author":"Etame","year":"2012","journal-title":"Neurosurg. Focus"},{"issue":"4","key":"10.1016\/j.arr.2022.101658_bib54","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3390\/nano10040787","article-title":"Stealth coating of nanoparticles in drug-delivery systems","volume":"10","author":"Fam","year":"2020","journal-title":"Nanomaterials"},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib55","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1080\/10717544.2018.1461955","article-title":"Curcumin-loaded PLGA-PEG nanoparticles conjugated with B6 peptide for potential use in Alzheimer's disease","volume":"25","author":"Fan","year":"2018","journal-title":"Drug Deliv."},{"issue":"38","key":"10.1016\/j.arr.2022.101658_bib56","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.2174\/0929867321666140915141836","article-title":"Nanotechnology and antioxidant therapy: an emerging approach for neurodegenerative diseases","volume":"21","author":"Fernandes","year":"2014","journal-title":"Curr. Med. Chem."},{"issue":"38","key":"10.1016\/j.arr.2022.101658_bib57","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.2174\/0929867321666140915141836","article-title":"Nanotechnology and antioxidant therapy: an emerging approach for neurodegenerative diseases","volume":"21","author":"Fernandes","year":"2014","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib58","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/0378-5173(89)90281-0","article-title":"Nanocapsule formation by interfacial polymer deposition following solvent displacement","volume":"55","author":"Fessi","year":"1989","journal-title":"Int. J. Pharm."},{"issue":"27","key":"10.1016\/j.arr.2022.101658_bib59","doi-asserted-by":"crossref","first-page":"15893","DOI":"10.1039\/C9RA09928J","article-title":"Sustained in vitro interferon-beta release and in vivo toxicity of PLGA and PEG-PLGA nanoparticles","volume":"10","author":"Fodor-Kardos","year":"2020","journal-title":"RSC Adv."},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib60","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s13311-013-0244-z","article-title":"Treatment of Huntington's disease","volume":"11","author":"Frank","year":"2014","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib61","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ijpharm.2011.05.049","article-title":"The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems\u2014a review","volume":"415","author":"Fredenberg","year":"2011","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.arr.2022.101658_bib62","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.tips.2004.06.002","article-title":"Importance of P-glycoprotein at blood-tissue barriers","volume":"25","author":"Fromm","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"issue":"10","key":"10.1016\/j.arr.2022.101658_bib63","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/s41593-018-0221-2","article-title":"Selective vulnerability in neurodegenerative diseases","volume":"21","author":"Fu","year":"2018","journal-title":"Nat. Neurosci."},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib64","doi-asserted-by":"crossref","first-page":"11086","DOI":"10.1038\/s41598-017-11611-4","article-title":"Ascorbic acid tethered polymeric nanoparticles enable efficient brain delivery of galantamine: an in vitro-in vivo study","volume":"7","author":"Gajbhiye","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.arr.2022.101658_bib65","doi-asserted-by":"crossref","first-page":"246","DOI":"10.5607\/en.2014.23.3.246","article-title":"Increasing the efficiency of Parkinson's disease treatment using a poly(lactic-co-glycolic acid) (PLGA) based L-DOPA delivery system","volume":"23","author":"Gambaryan","year":"2014","journal-title":"Exp. Neurobiol."},{"issue":"4","key":"10.1016\/j.arr.2022.101658_bib66","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3390\/molecules22040600","article-title":"Cellular Models and In Vitro Assays for the Screening of modulators of P-gp, MRP1 and BCRP","volume":"22","author":"Gameiro","year":"2017","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.arr.2022.101658_bib67","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/pharmaceutics10030116","article-title":"Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa","volume":"10","author":"Ganger","year":"2018","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib68","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12951-020-00626-1","article-title":"Neuron tau-targeting biomimetic nanoparticles for curcumin delivery to delay progression of Alzheimer's disease","volume":"18","author":"Gao","year":"2020","journal-title":"J. Nanobiotechnol."},{"issue":"4","key":"10.1016\/j.arr.2022.101658_bib69","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.apsb.2016.05.013","article-title":"Progress and perspectives on targeting nanoparticles for brain drug delivery","volume":"6","author":"Gao","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.arr.2022.101658_bib70","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.brainres.2011.04.049","article-title":"Amyotrophic lateral sclerosis: a neurovascular disease","volume":"1398","author":"Garbuzova-Davis","year":"2011","journal-title":"Brain Res."},{"issue":"9","key":"10.1016\/j.arr.2022.101658_bib71","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3109\/1061186X.2011.589435","article-title":"Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers","volume":"19","author":"Geldenhuys","year":"2011","journal-title":"J. Drug Target."},{"issue":"2","key":"10.1016\/j.arr.2022.101658_bib72","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejpb.2009.09.003","article-title":"Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters","volume":"74","author":"Gelperina","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.arr.2022.101658_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.matdes.2020.108805","article-title":"Review of hybrid PLGA nanoparticles: future of smart drug delivery and theranostics medicine","volume":"193","author":"Ghitman","year":"2020","journal-title":"Mater. Des."},{"issue":"3","key":"10.1016\/j.arr.2022.101658_bib74","doi-asserted-by":"crossref","first-page":"505","DOI":"10.34172\/apb.2021.058","article-title":"Prophylactic and therapeutic effects of MOG-conjugated PLGA nanoparticles in C57Bl\/6 mouse model of multiple sclerosis","volume":"11","author":"Gholamzad","year":"2021","journal-title":"Adv. Pharm. Bull."},{"issue":"8","key":"10.1016\/j.arr.2022.101658_bib75","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0028-3908(01)00019-3","article-title":"Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier","volume":"40","author":"Gilgun-Sherki","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2022.101658_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107554","article-title":"Dysfunction of ABC transporters at the blood-brain barrier: role in neurological disorders","volume":"213","author":"Gil-Martins","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.arr.2022.101658_bib77","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1021\/nn501292z","article-title":"Precision nanomedicine in neurodegenerative diseases","volume":"8","author":"Goldsmith","year":"2014","journal-title":"ACS Nano"},{"issue":"12","key":"10.1016\/j.arr.2022.101658_bib78","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2217\/nnm-2017-0023","article-title":"Delivery of siRNA silencing P-gp in peptide-functionalized nanoparticles causes efflux modulation at the blood\u2013brain barrier","volume":"12","author":"Gomes","year":"2017","journal-title":"Nanomedicine"},{"issue":"5","key":"10.1016\/j.arr.2022.101658_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/biom11050767","article-title":"Green tea Epigallocatechin-3-gallate (EGCG) targeting protein misfolding in drug discovery for neurodegenerative diseases","volume":"11","author":"Goncalves","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.arr.2022.101658_bib80","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neuropharm.2016.03.021","article-title":"The need for new approaches in CNS drug discovery: why drugs have failed, and what can be done to improve outcomes","volume":"120","author":"Gribkoff","year":"2017","journal-title":"Neuropharmacology"},{"issue":"31","key":"10.1016\/j.arr.2022.101658_bib81","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1016\/j.biomaterials.2011.07.004","article-title":"Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery","volume":"32","author":"Guo","year":"2011","journal-title":"Biomaterials"},{"issue":"11","key":"10.1016\/j.arr.2022.101658_bib82","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1021\/acs.molpharmaceut.8b00482","article-title":"Inhibitory effects of commonly used excipients on P-glycoprotein in vitro","volume":"15","author":"Gurjar","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.arr.2022.101658_bib83","series-title":"Engineering of Biomaterials for Drug Delivery Systems","first-page":"345","article-title":"Stealth coatings for nanoparticles: polyethylene glycol alternatives","author":"Hadjesfandiari","year":"2018"},{"issue":"2","key":"10.1016\/j.arr.2022.101658_bib84","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.3390\/ijms15021812","article-title":"Cell-based in vitro blood\u2013brain barrier model can rapidly evaluate nanoparticles\u2019 brain permeability in association with particle size and surface modification","volume":"15","author":"Hanada","year":"2014","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.arr.2022.101658_bib85","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am. J. Med."},{"issue":"2","key":"10.1016\/j.arr.2022.101658_bib86","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1124\/pr.57.2.4","article-title":"The blood-brain barrier\/neurovascular unit in health and disease","volume":"57","author":"Hawkins","year":"2005","journal-title":"Pharmacol. Rev."},{"issue":"9","key":"10.1016\/j.arr.2022.101658_bib87","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2174\/1381612822666151221150733","article-title":"Evolving drug delivery strategies to overcome the blood brain barrier","volume":"22","author":"Hersh","year":"2016","journal-title":"Curr. Pharm. Des."},{"issue":"3","key":"10.1016\/j.arr.2022.101658_bib88","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1208\/s12248-008-9055-2","article-title":"CNS delivery via adsorptive transcytosis","volume":"10","author":"Herve","year":"2008","journal-title":"AAPS J."},{"key":"10.1016\/j.arr.2022.101658_bib89","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jconrel.2015.10.006","article-title":"Control of polymeric nanoparticle size to improve therapeutic delivery","volume":"219","author":"Hickey","year":"2015","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.arr.2022.101658_bib90","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jconrel.2008.08.012","article-title":"The origins and evolution of \"controlled\" drug delivery systems","volume":"132","author":"Hoffman","year":"2008","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.arr.2022.101658_bib91","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41582-019-0244-7","article-title":"Ageing as a risk factor for neurodegenerative disease","volume":"15","author":"Hou","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib92","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ijpharm.2011.05.062","article-title":"Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease","volume":"415","author":"Hu","year":"2011","journal-title":"Int. J. Pharm."},{"issue":"46","key":"10.1016\/j.arr.2022.101658_bib93","doi-asserted-by":"crossref","first-page":"81001","DOI":"10.18632\/oncotarget.20944","article-title":"PLGA nanoparticles modified with a BBB-penetrating peptide co-delivering Abeta generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer's disease mice","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.arr.2022.101658_bib94","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1002\/jps.10176","article-title":"A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro","volume":"91","author":"Hugger","year":"2002","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.arr.2022.101658_bib95","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1021\/nn405033r","article-title":"A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease","volume":"8","author":"Hunter","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.arr.2022.101658_bib96","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jphotobiol.2018.11.008","article-title":"A novel synthesis of selenium nanoparticles encapsulated PLGA nanospheres with curcumin molecules for the inhibition of amyloid beta aggregation in Alzheimer's disease","volume":"190","author":"Huo","year":"2019","journal-title":"J. Photochem. Photobiol. B"},{"issue":"8","key":"10.1016\/j.arr.2022.101658_bib97","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25081929","article-title":"Intranasal delivery of nanoformulations: a potential way of treatment for neurological disorders","volume":"25","author":"Islam","year":"2020","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.arr.2022.101658_bib98","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nbd.2012.03.040","article-title":"Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS","volume":"47","author":"Jablonski","year":"2012","journal-title":"Neurobiol. Dis."},{"issue":"12","key":"10.1016\/j.arr.2022.101658_bib99","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/acn3.141","article-title":"Inhibiting drug efflux transporters improves efficacy of ALS therapeutics","volume":"1","author":"Jablonski","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"2","key":"10.1016\/j.arr.2022.101658_bib100","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/med.21528","article-title":"Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs","volume":"39","author":"Jaiswal","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.arr.2022.101658_bib101","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.nano.2019.02.004","article-title":"Vitamin D-binding protein-loaded PLGA nanoparticles suppress Alzheimer's disease-related pathology in 5XFAD mice","volume":"17","author":"Jeon","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.arr.2022.101658_bib102","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fbioe.2019.00261","article-title":"Hazard assessment of polymeric nanobiomaterials for drug delivery: what can we learn from literature so far","volume":"7","author":"Jesus","year":"2019","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"3","key":"10.1016\/j.arr.2022.101658_bib103","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3109\/03639040903170750","article-title":"The application of mucoadhesive polymers in nasal drug delivery","volume":"36","author":"Jiang","year":"2010","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"3","key":"10.1016\/j.arr.2022.101658_bib104","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.pbb.2008.01.016","article-title":"Dexibuprofen (S(+)-isomer ibuprofen) reduces microglial activation and impairments of spatial working memory induced by chronic lipopolysaccharide infusion","volume":"89","author":"Jin","year":"2008","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"4","key":"10.1016\/j.arr.2022.101658_bib105","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2217\/nnm.11.19","article-title":"Nanoparticle PEGylation for imaging and therapy","volume":"6","author":"Jokerst","year":"2011","journal-title":"Nanomedicine"},{"issue":"3","key":"10.1016\/j.arr.2022.101658_bib106","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1021\/acschemneuro.8b00545","article-title":"Biodegradable nanoparticles containing mechanism based peptide inhibitors reduce polyglutamine aggregation in cell models and alleviate motor symptoms in a Drosophila model of Huntington's disease","volume":"10","author":"Joshi","year":"2019","journal-title":"ACS Chem. Neurosci."},{"issue":"4","key":"10.1016\/j.arr.2022.101658_bib107","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1163\/156856003322699555","article-title":"Dexibuprofen: pharmacology, therapeutic uses and safety","volume":"11","author":"Kaehler","year":"2003","journal-title":"Inflammopharmacology"},{"issue":"2","key":"10.1016\/j.arr.2022.101658_bib108","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jconrel.2007.12.018","article-title":"Potential of solid lipid nanoparticles in brain targeting","volume":"127","author":"Kaur","year":"2008","journal-title":"J. Control. Release"},{"issue":"36","key":"10.1016\/j.arr.2022.101658_bib109","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1002\/anie.200902672","article-title":"Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives","volume":"49","author":"Knop","year":"2010","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.arr.2022.101658_bib110","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jconrel.2014.06.046","article-title":"PEG \u2014 a versatile conjugating ligand for drugs and drug delivery systems","volume":"192","author":"Kolate","year":"2014","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.arr.2022.101658_bib111","first-page":"1605","article-title":"L-Carnitine-conjugated nanoparticles to promote permeation across blood-brain barrier and to target glioma cells for drug delivery via the novel organic cation\/carnitine transporter OCTN2","volume":"46","author":"Kou","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"3","key":"10.1016\/j.arr.2022.101658_bib112","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/mds.25292","article-title":"The current and projected economic burden of Parkinson's disease in the United States","volume":"28","author":"Kowal","year":"2013","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib113","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0168-3659(01)00277-2","article-title":"Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C","volume":"72","author":"Kozlowski","year":"2001","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.arr.2022.101658_bib114","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/00006123-199805000-00082","article-title":"Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means","volume":"42","author":"Kroll","year":"1998","journal-title":"Neurosurgery"},{"key":"10.1016\/j.arr.2022.101658_bib115","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.colsurfb.2011.11.007","article-title":"Transcytosis of CRM197-grafted polybutylcyanoacrylate nanoparticles for delivering zidovudine across human brain-microvascular endothelial cells","volume":"91","author":"Kuo","year":"2012","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"20","key":"10.1016\/j.arr.2022.101658_bib116","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1016\/j.biomaterials.2013.03.013","article-title":"Targeting delivery of saquinavir to the brain using 83-14 monoclonal antibody-grafted solid lipid nanoparticles","volume":"34","author":"Kuo","year":"2013","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib117","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ijpharm.2011.06.037","article-title":"Transport of saquinavir across human brain-microvascular endothelial cells by poly(lactide-co-glycolide) nanoparticles with surface poly-(gamma-glutamic acid)","volume":"416","author":"Kuo","year":"2011","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.arr.2022.101658_bib118","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1080\/10611860903112842","article-title":"Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles","volume":"17","author":"Kurakhmaeva","year":"2009","journal-title":"J. Drug Target"},{"issue":"6","key":"10.1016\/j.arr.2022.101658_bib119","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson's disease","volume":"5","author":"de Lau","year":"2006","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.arr.2022.101658_bib120","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jconrel.2010.07.096","article-title":"Tumor targeting efficiency of bare nanoparticles does not mean the efficacy of loaded anticancer drugs: Importance of radionuclide imaging for optimization of highly selective tumor targeting polymeric nanoparticles with or without drug","volume":"147","author":"Lee","year":"2010","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.arr.2022.101658_bib121","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.taap.2004.10.012","article-title":"Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense","volume":"204","author":"Leslie","year":"2005","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"Pt A","key":"10.1016\/j.arr.2022.101658_bib122","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ijbiomac.2017.08.155","article-title":"Lactoferrin functionalized PEG-PLGA nanoparticles of shikonin for brain targeting therapy of glioma","volume":"107","author":"Li","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"issue":"3","key":"10.1016\/j.arr.2022.101658_bib123","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1515\/ntrev-2012-0084","article-title":"PLA\/PLGA nanoparticles for delivery of drugs across the blood-brain barrier","volume":"2","author":"Li","year":"2013","journal-title":"Nanotechnol. Rev."},{"issue":"7","key":"10.1016\/j.arr.2022.101658_bib124","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s11095-013-1025-4","article-title":"Brain delivery of NAP with PEG-PLGA nanoparticles modified with phage display peptides","volume":"30","author":"Li","year":"2013","journal-title":"Pharm. Res."},{"issue":"38","key":"10.1016\/j.arr.2022.101658_bib125","doi-asserted-by":"crossref","first-page":"21589","DOI":"10.1021\/acsami.5b07045","article-title":"Choline derivate-modified doxorubicin loaded micelle for glioma therapy","volume":"7","author":"Li","year":"2015","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"3","key":"10.1016\/j.arr.2022.101658_bib126","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.progpolymsci.2012.07.006","article-title":"Current drug research on PEGylation with small molecular agents","volume":"38","author":"Li","year":"2013","journal-title":"Prog. Polym. Sci."},{"key":"10.1016\/j.arr.2022.101658_bib127","first-page":"2473","article-title":"Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs","volume":"7","author":"Li","year":"2012","journal-title":"Int. J. Nanomed."},{"issue":"19","key":"10.1016\/j.arr.2022.101658_bib128","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1016\/j.biomaterials.2010.03.011","article-title":"A leptin derived 30-amino-acid peptide modified pegylated poly-L-lysine dendrigraft for brain targeted gene delivery","volume":"31","author":"Liu","year":"2010","journal-title":"Biomaterials"},{"issue":"6","key":"10.1016\/j.arr.2022.101658_bib129","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1021\/bc400055h","article-title":"B6 peptide-modified PEG-PLA nanoparticles for enhanced brain delivery of neuroprotective peptide","volume":"24","author":"Liu","year":"2013","journal-title":"Bioconjug. Chem."},{"issue":"4","key":"10.1016\/j.arr.2022.101658_bib130","first-page":"425","article-title":"Monoamine oxidase B inhibitors in Parkinson's disease","volume":"16","author":"Livia","year":"2017","journal-title":"CNS Neurol. Disord. Drug Targets"},{"issue":"9\u201310","key":"10.1016\/j.arr.2022.101658_bib131","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/10611860400015936","article-title":"Nanoparticle surface charges alter blood\u2013brain barrier integrity and permeability","volume":"12","author":"Lockman","year":"2004","journal-title":"J. Drug Target."},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib132","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pneurobio.2005.04.006","article-title":"Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases","volume":"76","author":"L\u00f6scher","year":"2005","journal-title":"Prog. Neurobiol."},{"issue":"5","key":"10.1016\/j.arr.2022.101658_bib133","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2217\/nnm.14.27","article-title":"Targeting nanoparticles across the blood-brain barrier with monoclonal antibodies","volume":"9","author":"Loureiro","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.arr.2022.101658_bib134","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.colsurfb.2016.04.041","article-title":"Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer's disease treatment","volume":"145","author":"Loureiro","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"18","key":"10.1016\/j.arr.2022.101658_bib135","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0142-9612(00)00047-8","article-title":"In vitro and in vivo degradation of porous poly(dl-lactic-co-glycolic acid) foams","volume":"21","author":"Lu","year":"2000","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.arr.2022.101658_bib136","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1517\/17425255.2016.1168804","article-title":"ABC transporters at the blood-brain barrier","volume":"12","author":"Mahringer","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"issue":"3","key":"10.1016\/j.arr.2022.101658_bib137","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","article-title":"Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier","volume":"3","author":"Makadia","year":"2011","journal-title":"Polymers"},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib138","article-title":"Functionalizing PLGA and PLGA derivatives for drug delivery and tissue regeneration applications","volume":"7","author":"Martins","year":"2018","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.arr.2022.101658_bib139","article-title":"Nanoparticles for brain drug delivery","volume":"2013","author":"Masserini","year":"2013","journal-title":"Int. Sch. Res. Not."},{"key":"10.1016\/j.arr.2022.101658_bib140","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/35040009","article-title":"Apoptosis in neurodegenerative disorders","volume":"1","author":"Mattson","year":"2000","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.arr.2022.101658_bib141","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3109\/03639045.2012.758130","article-title":"Preparation, characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting","volume":"40","author":"Md","year":"2014","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.arr.2022.101658_bib142","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3389\/fbioe.2020.00224","article-title":"Intravenously administered, retinoid activating nanoparticles increase lifespan and reduce neurodegeneration in the SOD1(G93A) mouse model of ALS","volume":"8","author":"Medina","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.arr.2022.101658_bib143","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2147\/IJN.S151474","article-title":"Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer's disease","volume":"13","author":"Meng","year":"2018","journal-title":"Int. J. Nanomed."},{"issue":"6","key":"10.1016\/j.arr.2022.101658_bib144","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1191\/1352458503ms965oa","article-title":"Blood-brain barrier disruption in multiple sclerosis","volume":"9","author":"Minagar","year":"2003","journal-title":"Mult. Scler."},{"key":"10.1016\/j.arr.2022.101658_bib145","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.colsurfb.2017.07.038","article-title":"Recent applications of PLGA based nanostructures in drug delivery","volume":"159","author":"Mir","year":"2017","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"2","key":"10.1016\/j.arr.2022.101658_bib146","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.arr.2022.101658_bib147","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jconrel.2010.11.013","article-title":"Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer's pathology","volume":"150","author":"Mittal","year":"2011","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.arr.2022.101658_bib148","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.bbrc.2012.01.155","article-title":"Real-time analysis of P-glycoprotein-mediated drug transport across primary intestinal epithelium three-dimensionally cultured in vitro","volume":"419","author":"Mizutani","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.arr.2022.101658_bib149","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.expneurol.2019.04.002","article-title":"Excess glutamate secreted from astrocytes drives upregulation of P-glycoprotein in endothelial cells in amyotrophic lateral sclerosis","volume":"316","author":"Mohamed","year":"2019","journal-title":"Exp. Neurol."},{"issue":"2","key":"10.1016\/j.arr.2022.101658_bib150","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jcis.2007.09.081","article-title":"Mechanism of nanocapsules formation by the emulsion-diffusion process","volume":"317","author":"Moinard-Checot","year":"2008","journal-title":"J. Colloid Interface Sci."},{"issue":"10","key":"10.1016\/j.arr.2022.101658_bib151","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1021\/acs.jmedchem.7b00527","article-title":"Aptamer functionalization of nanosystems for glioblastoma targeting through the blood-brain barrier","volume":"60","author":"Monaco","year":"2017","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib152","doi-asserted-by":"crossref","first-page":"15185","DOI":"10.1038\/s41598-021-94175-8","article-title":"Dopamine-loaded nanoparticle systems circumvent the blood\u2013brain barrier restoring motor function in mouse model for Parkinson\u2019s Disease","volume":"11","author":"Monge-Fuentes","year":"2021","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.arr.2022.101658_bib153","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/17425247.2019.1583205","article-title":"Blood-brain barrier receptors and transporters: an insight on their function and how to exploit them through nanotechnology","volume":"16","author":"Moura","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"issue":"0","key":"10.1016\/j.arr.2022.101658_bib154","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijbiomac.2013.04.024","article-title":"Optimization of brain targeted chitosan nanoparticles of Rivastigmine for improved efficacy and safety","volume":"59","author":"Nagpal","year":"2013","journal-title":"Int. J. Biol. Macromol."},{"issue":"14","key":"10.1016\/j.arr.2022.101658_bib155","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143387","article-title":"Polyester polymeric nanoparticles as platforms in the development of novel nanomedicines for cancer treatment","volume":"13","author":"Niza","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.arr.2022.101658_bib156","doi-asserted-by":"crossref","first-page":"746","DOI":"10.2174\/156720512801322564","article-title":"N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease","volume":"9","author":"Olivares","year":"2012","journal-title":"Curr. Alzheimer Res."},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib157","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/ciia.2007.2.1.17","article-title":"Rivastigmine in the treatment of Alzheimer\u2019s disease: an update","volume":"2","author":"Onor","year":"2007","journal-title":"Clin. Interv. Aging"},{"issue":"8","key":"10.1016\/j.arr.2022.101658_bib158","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.arcmed.2014.11.013","article-title":"Role of the blood-brain barrier in multiple sclerosis","volume":"45","author":"Ortiz","year":"2014","journal-title":"Arch. Med. Res."},{"issue":"2","key":"10.1016\/j.arr.2022.101658_bib159","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201700489","article-title":"In vitro microfluidic models for neurodegenerative disorders","volume":"7","author":"Osaki","year":"2018","journal-title":"Adv. Healthc. Mater."},{"issue":"7","key":"10.1016\/j.arr.2022.101658_bib160","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/jnnp-2014-308764","article-title":"Cholinesterase inhibitors for Parkinson's disease: a systematic review and meta-analysis","volume":"86","author":"Pagano","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.arr.2022.101658_bib161","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1021\/nn506408v","article-title":"Trans-blood brain barrier delivery of dopamine-loaded nanoparticles reverses functional deficits in parkinsonian rats","volume":"9","author":"Pahuja","year":"2015","journal-title":"ACS Nano"},{"issue":"4","key":"10.1016\/j.arr.2022.101658_bib162","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","article-title":"Medicinal chemical properties of successful central nervous system drugs","volume":"2","author":"Pajouhesh","year":"2005","journal-title":"NeuroRx"},{"issue":"4","key":"10.1016\/j.arr.2022.101658_bib163","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3233\/JAD-2011-110368","article-title":"The role of the blood brain barrier in neurodegenerative disorders and their treatment","volume":"24","author":"Palmer","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2022.101658_bib164","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.addr.2018.04.009","article-title":"Impact of aging, Alzheimer's disease and Parkinson's disease on the blood-brain barrier transport of therapeutics","volume":"135","author":"Pan","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"10.1016\/j.arr.2022.101658_bib165","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1517\/17425247.2013.790887","article-title":"Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting","volume":"10","author":"Pardeshi","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib166","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib167","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.drudis.2006.10.013","article-title":"Blood\u2013brain barrier delivery","volume":"12","author":"Pardridge","year":"2007","journal-title":"Drug Discov. Today"},{"issue":"3","key":"10.1016\/j.arr.2022.101658_bib168","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ejpb.2009.11.001","article-title":"Efficacy of surface charge in targeting pegylated nanoparticles of sulpiride to the brain","volume":"74","author":"Parikh","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.arr.2022.101658_bib169","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.nano.2011.05.016","article-title":"Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging","volume":"8","author":"Parveen","year":"2012","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib170","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib171","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12951-022-01269-0","article-title":"Unconjugated PLGA nanoparticles attenuate temperature-dependent beta-amyloid aggregation and protect neurons against toxicity: implications for Alzheimer's disease pathology","volume":"20","author":"Paul","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.arr.2022.101658_bib172","first-page":"3","article-title":"Synthesis applications of gold nanoparticles","volume":"vol. 4","author":"Pelaz","year":"2012"},{"issue":"21","key":"10.1016\/j.arr.2022.101658_bib173","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111654","article-title":"Nanoparticles for targeted brain drug delivery: what do we know?","volume":"22","author":"Pinheiro","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"36","key":"10.1016\/j.arr.2022.101658_bib174","doi-asserted-by":"crossref","first-page":"16962","DOI":"10.1039\/C8NR04073G","article-title":"Treatment of neurodegenerative disorders through the blood-brain barrier using nanocarriers","volume":"10","author":"Poovaiah","year":"2018","journal-title":"Nanoscale"},{"issue":"4","key":"10.1016\/j.arr.2022.101658_bib175","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190062","article-title":"The blood-brain barrier in health and disease: important unanswered questions","volume":"217","author":"Profaci","year":"2020","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.arr.2022.101658_bib176","doi-asserted-by":"crossref","first-page":"111","DOI":"10.31887\/DCNS.2009.11.2\/cqiu","article-title":"Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention","volume":"11","author":"Qiu","year":"2009","journal-title":"Dialog. Clin. Neurosci."},{"issue":"Pt B","key":"10.1016\/j.arr.2022.101658_bib177","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.brainres.2015.07.005","article-title":"Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders","volume":"1628","author":"Qosa","year":"2015","journal-title":"Brain Res."},{"issue":"23","key":"10.1016\/j.arr.2022.101658_bib178","doi-asserted-by":"crossref","DOI":"10.3390\/polym13234114","article-title":"Development of polymer-based nanoformulations for glioblastoma brain cancer therapy and diagnosis: an update","volume":"13","author":"Rabha","year":"2021","journal-title":"Polymers"},{"issue":"3","key":"10.1016\/j.arr.2022.101658_bib179","article-title":"Polymeric nanoparticles for nasal drug delivery to the brain: relevance to Alzheimer's disease","volume":"4","author":"Rabiee","year":"2021","journal-title":"Adv. Ther."},{"issue":"7","key":"10.1016\/j.arr.2022.101658_bib180","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/17425247.2016.1244187","article-title":"Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures","volume":"14","author":"Ragelle","year":"2017","journal-title":"Expert Opin. Drug Deliv."},{"issue":"12","key":"10.1016\/j.arr.2022.101658_bib181","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1084\/jem.20182042","article-title":"All (animal) models (of neurodegeneration) are wrong. Are they also useful?","volume":"215","author":"Ransohoff","year":"2018","journal-title":"J. Exp. Med."},{"issue":"33","key":"10.1016\/j.arr.2022.101658_bib182","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1016\/j.biomaterials.2008.08.004","article-title":"TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs","volume":"29","author":"Rao","year":"2008","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.arr.2022.101658_bib183","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1023\/A:1007049806660","article-title":"Osmotic opening of the blood\u2013brain barrier: principles, mechanism, and therapeutic applications","volume":"20","author":"Rapoport","year":"2000","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.arr.2022.101658_bib184","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.3389\/fphar.2018.01260","article-title":"PLGA-based nanoparticles in cancer treatment","volume":"9","author":"Rezvantalab","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.arr.2022.101658_bib185","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.biomaterials.2015.03.044","article-title":"Myelin repair in vivo is increased by targeting oligodendrocyte precursor cells with nanoparticles encapsulating leukaemia inhibitory factor (LIF)","volume":"56","author":"Rittchen","year":"2015","journal-title":"Biomaterials"},{"issue":"7","key":"10.1016\/j.arr.2022.101658_bib186","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1038\/s41380-021-01055-8","article-title":"Current and future applications of induced pluripotent stem cell-based models to study pathological proteins in neurodegenerative disorders","volume":"26","author":"de Rus Jacquet","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.arr.2022.101658_bib187","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fpubh.2018.00181","article-title":"Phenotypic heterogeneity in dementia: a challenge for epidemiology and biomarker studies","volume":"6","author":"Ryan","year":"2018","journal-title":"Front. Public Health"},{"issue":"8","key":"10.1016\/j.arr.2022.101658_bib188","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20081829","article-title":"Recent developments in metal-based drugs and chelating agents for neurodegenerative diseases treatments","volume":"20","author":"Sales","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2022.101658_bib189","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.addr.2019.01.012","article-title":"A window into the brain: tools to assess pre-clinical efficacy of biomaterials-based therapies on central nervous system disorders","volume":"148","author":"Samal","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.arr.2022.101658_bib190","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.nano.2016.12.003","article-title":"New potential strategies for Alzheimer's disease prevention: pegylated biodegradable dexibuprofen nanospheres administration to APPswe\/PS1dE9","volume":"13","author":"Sanchez-Lopez","year":"2017","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib191","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12951-018-0356-z","article-title":"Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: in vitro and in vivo characterization","volume":"16","author":"Sanchez-Lopez","year":"2018","journal-title":"J. Nanobiotechnol."},{"issue":"Supplement C","key":"10.1016\/j.arr.2022.101658_bib192","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","article-title":"Nanoparticle-mediated brain drug delivery: overcoming blood\u2013brain barrier to treat neurodegenerative diseases","volume":"235","author":"Saraiva","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.arr.2022.101658_bib193","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jconrel.2016.06.005","article-title":"MicroRNA-124 loaded nanoparticles enhance brain repair in Parkinson's disease","volume":"235","author":"Saraiva","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.arr.2022.101658_bib194","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2019.110962","article-title":"Phytol loaded PLGA nanoparticles regulate the expression of Alzheimer's related genes and neuronal apoptosis against amyloid-beta induced toxicity in Neuro-2a cells and transgenic Caenorhabditis elegans","volume":"136","author":"Sathya","year":"2020","journal-title":"Food Chem. Toxicol."},{"issue":"7\u20138","key":"10.1016\/j.arr.2022.101658_bib195","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3109\/1061186X.2015.1065833","article-title":"Systemic delivery of blood-brain barrier-targeted polymeric nanoparticles enhances delivery to brain tissue","volume":"23","author":"Saucier-Sawyer","year":"2015","journal-title":"J. Drug Target."},{"issue":"4","key":"10.1016\/j.arr.2022.101658_bib196","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1586\/14737175.7.4.407","article-title":"Dementia syndromes: evaluation and treatment","volume":"7","author":"Scott","year":"2007","journal-title":"Expert Rev. Neurother."},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib197","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1042\/bse0500161","article-title":"The P-glycoprotein multidrug transporter","volume":"50","author":"Sharom","year":"2011","journal-title":"Essays Biochem."},{"key":"10.1016\/j.arr.2022.101658_bib198","first-page":"8","article-title":"Neurodegenerative diseases: multifactorial conformational diseases and their therapeutic interventions","volume":"2013","author":"Sheikh","year":"2013","journal-title":"J. Neurodegener. Dis."},{"issue":"1\u20132","key":"10.1016\/j.arr.2022.101658_bib199","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijpharm.2006.01.020","article-title":"Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies","volume":"313","author":"Shen","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.arr.2022.101658_bib200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2014.11.013","article-title":"Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy","volume":"149","author":"Silva","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.arr.2022.101658_bib201","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.2147\/IJN.S171490","article-title":"PPARgamma agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer's disease: in vitro and in vivo studies","volume":"13","author":"Silva-Abreu","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.arr.2022.101658_bib202","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3389\/fcell.2020.00328","article-title":"In vitro models of neurodegenerative diseases","volume":"8","author":"Slanzi","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"5","key":"10.1016\/j.arr.2022.101658_bib203","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.nantod.2011.08.001","article-title":"Cellular toxicity of inorganic nanoparticles: common aspects and guidelines for improved nanotoxicity evaluation","volume":"6","author":"Soenen","year":"2011","journal-title":"Nano Today"},{"issue":"2","key":"10.1016\/j.arr.2022.101658_bib204","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.colsurfb.2008.07.004","article-title":"Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size","volume":"66","author":"Sonavane","year":"2008","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib205","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/pharmaceutics10010034","article-title":"Surface-modified nanocarriers for nose-to-brain delivery: from bioadhesion to targeting","volume":"10","author":"Sonvico","year":"2018","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.arr.2022.101658_bib206","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2174\/187152712800672436","article-title":"Role of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson\u2019s disease and L-DOPA treatment","volume":"11","author":"Stefano","year":"2012","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.arr.2022.101658_bib207","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.colsurfb.2016.08.052","article-title":"Design of PLGA-functionalized quercetin nanoparticles for potential use in Alzheimer's disease","volume":"148","author":"Sun","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"6","key":"10.1016\/j.arr.2022.101658_bib208","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nn.4288","article-title":"Pericytes of the neurovascular unit: key functions and signaling pathways","volume":"19","author":"Sweeney","year":"2016","journal-title":"Nat. Neurosci."},{"issue":"3","key":"10.1016\/j.arr.2022.101658_bib209","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2022.101658_bib210","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.actbio.2018.04.006","article-title":"Customizing poly(lactic-co-glycolic acid) particles for biomedical applications","volume":"73","author":"Swider","year":"2018","journal-title":"Acta Biomater."},{"issue":"4","key":"10.1016\/j.arr.2022.101658_bib211","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1517\/14728214.2015.1113254","article-title":"What is the future of PEGylated therapies?","volume":"20","author":"Swierczewska","year":"2015","journal-title":"Expert Opin. Emerg. Drugs"},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib212","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1080\/10717544.2019.1636420","article-title":"Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson's disease","volume":"26","author":"Tang","year":"2019","journal-title":"Drug Deliv."},{"key":"10.1016\/j.arr.2022.101658_bib213","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.freeradbiomed.2013.07.042","article-title":"Nicotine-encapsulated poly(lactic-co-glycolic) acid nanoparticles improve neuroprotective efficacy against MPTP-induced parkinsonism","volume":"65","author":"Tiwari","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.arr.2022.101658_bib214","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/j.2040-4603.2012.tb00402.x","article-title":"Structure and composition of pulmonary arteries, capillaries and veins","volume":"2","author":"Townsley","year":"2012","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.arr.2022.101658_bib215","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev.neuro.30.051606.094313","article-title":"Multiple sclerosis: an immune or neurodegenerative disorder?","volume":"31","author":"Trapp","year":"2008","journal-title":"Annu. Rev. Neurosci."},{"issue":"3","key":"10.1016\/j.arr.2022.101658_bib216","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.tins.2021.12.004","article-title":"Lysosomal dysfunction in neurodegeneration: emerging concepts and methods","volume":"45","author":"Udayar","year":"2022","journal-title":"Trends Neurosci."},{"issue":"2","key":"10.1016\/j.arr.2022.101658_bib217","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/10611861003734001","article-title":"Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB)","volume":"19","author":"Ulbrich","year":"2011","journal-title":"J. Drug Target"},{"issue":"12","key":"10.1016\/j.arr.2022.101658_bib218","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/polb.22259","article-title":"Biomedical applications of biodegradable polymers","volume":"49","author":"Ulery","year":"2011","journal-title":"J. Polym. Sci. B Polym. Phys."},{"key":"10.1016\/j.arr.2022.101658_bib219","unstructured":"P.D. United Nations Department of Economic and Social Affairs World Population Ageing 2020 Highlights: living arrangements of older persons (ST\/ESA\/SER.A\/451), 2020."},{"issue":"5","key":"10.1016\/j.arr.2022.101658_bib220","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s12272-021-01332-8","article-title":"Blood-brain barrier dysfunction as a potential therapeutic target for neurodegenerative disorders","volume":"44","author":"Uprety","year":"2021","journal-title":"Arch. Pharm. Res."},{"issue":"12","key":"10.1016\/j.arr.2022.101658_bib221","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.15252\/emmm.201505413","article-title":"Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice","volume":"7","author":"Valenza","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.arr.2022.101658_bib222","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jtemb.2017.12.006","article-title":"Reduced plaque size and inflammation in the APP23 mouse model for Alzheimer's disease after chronic application of polymeric nanoparticles for CNS targeted zinc delivery","volume":"49","author":"Vilella","year":"2018","journal-title":"J. Trace Elem. Med. Biol."},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib223","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejpb.2014.02.013","article-title":"Surfactants, not size or zeta-potential influence blood-brain barrier passage of polymeric nanoparticles","volume":"87","author":"Voigt","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.arr.2022.101658_bib224","unstructured":"W. H. Organization Global action plan on the public health response to dementia 2017\u20132025, 2017."},{"issue":"5","key":"10.1016\/j.arr.2022.101658_bib225","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.biomaterials.2009.09.104","article-title":"Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain","volume":"31","author":"Wang","year":"2010","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.arr.2022.101658_bib226","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1446","article-title":"Recent advances in aliphatic polyesters for drug delivery applications","volume":"9","author":"Washington","year":"2017","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"issue":"4","key":"10.1016\/j.arr.2022.101658_bib227","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.bbamem.2008.10.022","article-title":"The blood-brain barrier in brain homeostasis and neurological diseases","volume":"1788","author":"Weiss","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.arr.2022.101658_bib228","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jconrel.2011.02.022","article-title":"Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration","volume":"151","author":"Wen","year":"2011","journal-title":"J. Control. Release"},{"issue":"14","key":"10.1016\/j.arr.2022.101658_bib229","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147710","article-title":"Blood-brain barrier and neurodegenerative diseases-modeling with iPSC-derived brain cells","volume":"22","author":"Wu","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"32","key":"10.1016\/j.arr.2022.101658_bib230","doi-asserted-by":"crossref","first-page":"8167","DOI":"10.1016\/j.biomaterials.2012.07.046","article-title":"Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles","volume":"33","author":"Xin","year":"2012","journal-title":"Biomaterials"},{"issue":"17","key":"10.1016\/j.arr.2022.101658_bib231","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1523\/JNEUROSCI.5103-08.2009","article-title":"ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides","volume":"29","author":"Xiong","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2022.101658_bib232","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2147\/IJN.S236922","article-title":"Rhynchophylline loaded-mPEG-PLGA nanoparticles coated with Tween-80 for preliminary study in Alzheimer's disease","volume":"15","author":"Xu","year":"2020","journal-title":"Int. J. Nanomed."},{"issue":"34","key":"10.1016\/j.arr.2022.101658_bib233","doi-asserted-by":"crossref","first-page":"9764","DOI":"10.1021\/acs.jafc.1c00569","article-title":"PLGA-PEG nanoparticles facilitate in vivo anti-Alzheimer's effects of fucoxanthin, a marine carotenoid derived from edible brown algae","volume":"69","author":"Yang","year":"2021","journal-title":"J. Agric. Food Chem."},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib234","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1756285612461679","article-title":"Current and future treatments for Alzheimer\u2019s disease","volume":"6","author":"Yiannopoulou","year":"2013","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"5","key":"10.1016\/j.arr.2022.101658_bib235","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1039\/C9NR08741A","article-title":"Penetration of the blood-brain barrier and the anti-tumour effect of a novel PLGA-lysoGM1\/DOX micelle drug delivery system","volume":"12","author":"Yin","year":"2020","journal-title":"Nanoscale"},{"issue":"5","key":"10.1016\/j.arr.2022.101658_bib236","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1021\/acsnano.7b08172","article-title":"Targeted brain delivery of rabies virus glycoprotein 29-modified deferoxamine-loaded nanoparticles reverses functional deficits in Parkinsonian mice","volume":"12","author":"You","year":"2018","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib237","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1038\/s41467-018-05892-0","article-title":"I. Alzheimer's Disease Neuroimaging, Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference","volume":"9","author":"Young","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib238","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11095-011-0513-7","article-title":"Self-assembled polymersomes conjugated with lactoferrin as novel drug carrier for brain delivery","volume":"29","author":"Yu","year":"2012","journal-title":"Pharm. Res."},{"issue":"31","key":"10.1016\/j.arr.2022.101658_bib239","doi-asserted-by":"crossref","first-page":"13910","DOI":"10.1021\/acs.iecr.9b02003","article-title":"Biodegradable PLGA nanoparticles restore lysosomal acidity and protect neural PC-12 cells against mitochondrial toxicity","volume":"58","author":"Zeng","year":"2019","journal-title":"Ind. Eng. Chem. Res."},{"issue":"24","key":"10.1016\/j.arr.2022.101658_bib240","doi-asserted-by":"crossref","first-page":"5482","DOI":"10.1002\/anie.201100875","article-title":"Micelle-based brain-targeted drug delivery enabled by a nicotine acetylcholine receptor ligand","volume":"50","author":"Zhan","year":"2011","journal-title":"Angew. Chem. Int. Ed."},{"issue":"1","key":"10.1016\/j.arr.2022.101658_bib241","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.biomaterials.2013.09.063","article-title":"Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice","volume":"35","author":"Zhang","year":"2014","journal-title":"Biomaterials"},{"issue":"1\u20132","key":"10.1016\/j.arr.2022.101658_bib242","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijpharm.2013.11.049","article-title":"Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer's disease","volume":"461","author":"Zhang","year":"2014","journal-title":"Int. J. Pharm."},{"issue":"9","key":"10.1016\/j.arr.2022.101658_bib243","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/BF02976689","article-title":"Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats","volume":"26","author":"Zhang","year":"2003","journal-title":"Arch. Pharm. Res."},{"issue":"24","key":"10.1016\/j.arr.2022.101658_bib244","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.201910691","article-title":"A conditionally releasable \u201cDo not Eat Me\u201d CD47 signal facilitates microglia-targeted drug delivery for the treatment of Alzheimer's disease","volume":"30","author":"Zhang","year":"2020","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.arr.2022.101658_bib245","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.2147\/IJN.S138501","article-title":"Cyclic hexapeptide-conjugated nanoparticles enhance curcumin delivery to glioma tumor cells and tissue","volume":"12","author":"Zhang","year":"2017","journal-title":"Int. J. Nanomed."},{"issue":"4","key":"10.1016\/j.arr.2022.101658_bib246","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13040500","article-title":"PLGA nanoparticle-based formulations to cross the blood-brain barrier for drug delivery: from R&D to cGMP","volume":"13","author":"Zhi","year":"2021","journal-title":"Pharmaceutics"}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163722001003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163722001003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:08:43Z","timestamp":1761592123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163722001003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":246,"alternative-id":["S1568163722001003"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2022.101658","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brain drug delivery and neurodegenerative diseases: Polymeric PLGA-based nanoparticles as a forefront platform","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2022.101658","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101658"}}